Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (261-270 of 467) with videos related to

Pageof 47
Sort By:
International Journal of Antimicrobial Agents|March 4, 2023
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimenRossana Scutari, Laura Galli, Claudia Alteri, et al.
Journal of Medical Virology|December 1, 2023
Mpox DNA clearance in semen over 6-month follow-upCaterina Candela, Laura Galli, Alberto Rizzo, et al.
HIV Medicine|April 18, 2026
Three settings, one goal: Performance of different HIV testing strategies at a tertiary centre in MilanAngelo Roberto Raccagni, Riccardo Lolatto, Nicolò Capra, et al.
HIV Clinical Trials|March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
BMC Infectious Diseases|June 12, 2021
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIVEsther Merlini, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
AIDS (London, England)|November 15, 2023
Sexually transmitted infections in people with multidrug-resistant HIVTommaso Clemente, Riccardo Lolatto, Rebecka Papaioannu Borjesson, et al.
The Journal of Clinical Investigation|September 29, 2020
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domainMassimiliano Secchi, Elena Bazzigaluppi, Cristina Brigatti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2021
Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA CohortAndrea Giacomelli, Alessandro Cozzi-Lepri, Antonella Cingolani, et al.
Journal of the International AIDS Society|November 15, 2014
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT studyVincenzo Spagnuolo, Laura Galli, Alba Bigoloni, et al.
Antiviral Therapy|April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna, Laura Galli, Carlo Torti, et al.
Pageof 47

Showing results (261-270 of 467) with videos related to

Sort By:
Pageof 47
International Journal of Antimicrobial Agents|March 4, 2023
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimenRossana Scutari, Laura Galli, Claudia Alteri, et al.
Journal of Medical Virology|December 1, 2023
Mpox DNA clearance in semen over 6-month follow-upCaterina Candela, Laura Galli, Alberto Rizzo, et al.
HIV Medicine|April 18, 2026
Three settings, one goal: Performance of different HIV testing strategies at a tertiary centre in MilanAngelo Roberto Raccagni, Riccardo Lolatto, Nicolò Capra, et al.
HIV Clinical Trials|March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
BMC Infectious Diseases|June 12, 2021
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIVEsther Merlini, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
AIDS (London, England)|November 15, 2023
Sexually transmitted infections in people with multidrug-resistant HIVTommaso Clemente, Riccardo Lolatto, Rebecka Papaioannu Borjesson, et al.
The Journal of Clinical Investigation|September 29, 2020
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domainMassimiliano Secchi, Elena Bazzigaluppi, Cristina Brigatti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2021
Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA CohortAndrea Giacomelli, Alessandro Cozzi-Lepri, Antonella Cingolani, et al.
Journal of the International AIDS Society|November 15, 2014
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT studyVincenzo Spagnuolo, Laura Galli, Alba Bigoloni, et al.
Antiviral Therapy|April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna, Laura Galli, Carlo Torti, et al.
Pageof 47